Share on StockTwits

Intercept Pharmaceuticals (NASDAQ:ICPT) Director Klaus R. Dr Veitinger sold 316 shares of Intercept Pharmaceuticals stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $345.62, for a total transaction of $109,215.92. Following the sale, the director now directly owns 2,166 shares in the company, valued at approximately $748,613. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) traded down 3.93% during mid-day trading on Friday, hitting $284.70. The stock had a trading volume of 586,794 shares. Intercept Pharmaceuticals has a 52 week low of $42.41 and a 52 week high of $497.00. The stock’s 50-day moving average is $236.1 and its 200-day moving average is $291.9. The company’s market cap is $6.040 billion.

Intercept Pharmaceuticals (NASDAQ:ICPT) last released its earnings data on Monday, August 11th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.12) by $0.67. The company had revenue of $405.40 million for the quarter, compared to the consensus estimate of $400.00 million. Analysts expect that Intercept Pharmaceuticals will post $-13.46 EPS for the current fiscal year.

Several analysts have recently commented on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Intercept Pharmaceuticals in a research note on Friday. They set an “underperform” rating and a $172.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of Intercept Pharmaceuticals to a “hold” rating in a research note on Thursday. Finally, analysts at Nomura upgraded shares of Intercept Pharmaceuticals to a “positive” rating in a research note on Tuesday. They now have a $456.00 price target on the stock, up previously from $323.00. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $472.91.

Intercept Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat chronic liver diseases utilizing its bile acid chemistry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.